What should I do if I become resistant to Secukinumab?

Secukinumab is a fully human monoclonal antibody that selectively binds and neutralizes IL-17A. It is approved for use as a subcutaneous injection to treat moderate to severe psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). The long-term extension of the pivotal trial demonstrated the sustainable efficacy and safety of secukinumab in PsA for up to 5 years.

20.23% of patients discontinued treatment during follow-up, mainly due to primary and secondary loss of efficacy, and 15 patients withdrew from the observational study. Only 22 patients suspended secukinumab due to adverse events named injection site reaction, 1 leukopenia-neutropenia, 1 hypertransaminasemia, 2 dyspnea, 1 multiple sclerosis, and 6 severe recurrent infections. Liver and renal function were monitored in all patients during the study period, with only two patients showing abnormal values.

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.